Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
18.01
-0.58 (-3.12%)
At close: Apr 28, 2026, 4:00 PM EDT
17.65
-0.36 (-2.00%)
After-hours: Apr 28, 2026, 7:07 PM EDT
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Zenas BioPharma stock have an average target of 42.14, with a low estimate of 21 and a high estimate of 55. The average target predicts an increase of 133.98% from the current stock price of 18.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 17, 2026.
Analyst Ratings
The average analyst rating for Zenas BioPharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 4 | 3 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $43 → $41 | Strong Buy | Maintains | $43 → $41 | +127.65% | Mar 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $45 → $55 | Strong Buy | Maintains | $45 → $55 | +205.39% | Mar 17, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $19 → $21 | Hold | Maintains | $19 → $21 | +16.60% | Mar 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +144.31% | Mar 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +144.31% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
18.08M
from 10.00M
Increased by 80.83%
Revenue Next Year
51.63M
from 18.08M
Increased by 185.49%
EPS This Year
-5.14
from -8.44
EPS Next Year
-4.89
from -5.14
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 74.5M | 86.1M | ||||||
| Avg | 18.1M | 51.6M | ||||||
| Low | n/a | 22.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 644.6% | 376.1% | ||||||
| Avg | 80.8% | 185.5% | ||||||
| Low | - | 25.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -4.61 | -3.85 | |||
| Avg | -5.14 | -4.89 | |||
| Low | -6.06 | -5.64 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.